Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
8.53
-0.11 (-1.27%)
Sep 10, 2026, 10:18 AM EDT - Market open
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
495.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| ARS Pharmaceuticals | 116.93M |
| Scribe Therapeutics | 33.30M |
| Prelude Therapeutics | 22.42M |
| Ovid Therapeutics | 1.58M |
| Artiva Biotherapeutics | 251.00K |
| Entera Bio | 42.00K |
CAPR News
- 1 day ago - LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation - Business Wire
- 3 days ago - Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline - GlobeNewsWire
- 5 days ago - Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Act Ahead of the Lead Plaintiff Deadline on September 28, 2026 - Newsfile Corp
- 6 days ago - Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026 - GlobeNewsWire
- 7 days ago - Kaplan Fox Alerts Capricor Therapeutics, Inc. (CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026 - Newsfile Corp
- 8 days ago - Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 - GlobeNewsWire
- 8 days ago - $CAPR News: Capricor Therapeutics Sued for Securities Fraud Over Alleged Misrepresentations about its Clinical Data – Contact BFA Law by September 28 if You Lost Money - GlobeNewsWire
- 8 days ago - Kaplan Fox Urges Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026 - Newsfile Corp